{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-282945","form_type":"8-K/A","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2021-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.300281+00:00","generated_at":"2026-06-29T01:19:16.271558+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Solid Biosciences corrects FVC data error for patient five in IGNITE DMD trial; mean improvement +8.5%","bullets":["Corrected 1.5-year FVC change for patient five: +22.5% (previously reported incorrectly).","Mean percent predicted FVC improvement for patients 4-6: +8.5% (range +0.6% to +22.5%).","Mean difference vs natural history decline of 7.5% was +16.0% over 1.5 years.","All three patients treated with 2E14 vg/kg SGT-001 show stability or improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-282945","json":"https://secwatch.observer/filing/0001193125-21-282945.json","markdown":"https://secwatch.observer/filing/0001193125-21-282945.md","text":"https://secwatch.observer/filing/0001193125-21-282945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521282945/0001193125-21-282945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312521282945/d231696d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:19:16.271558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}